Added value of this study
CKD, diabetes
DIABETES
These analyses show that empagliflozin caused a modest initial drop in kidney
function, followed by a substantial slowing of the rate of progression of CKD in
all patients. These ‘chronic’ effects varied by baseline diabetes
status, eGFR and uACR in both absolute and relative terms, and these
interactions were independent of each other. In particular, the absolute
difference in chronic slopes was lower in those with lower baseline uACR, but
because this group progressed more slowly than those with higher uACR, this
translated to a larger relative difference in chronic slopes in this group.